| 41 |
Design, synthesis, and biological evaluation of novel quinoline-based EGFR/HER-2 dual-target inhibitors as potential antitumor agents |
2024 |
| 42 |
Design, synthesis, biological evaluation and docking study of some new aryl and heteroaryl thiomannosides as FimH antagonists. |
2024 |
| 43 |
Discovery of new Schiff bases of the disalicylic acid scaffold as DNA gyrase and Topoisomerase IV inhibitors endowed with antibacterial properties |
2024 |
| 44 |
Hybrids of 4-aminosalicylic acid with dual anti-mycobacterial and anti-inflammatory activities: Synthesis, biological evaluation, in silico investigation and structure-activity relationships exploration |
2024 |
| 45 |
Neu5Gc-mediated high affinity interaction is dispensable for CD22 cis-ligands to regulate B cell signaling |
2024 |
| 46 |
New diaryl-1,2,4-triazolo[3,4-a]pyrimidine hybrids as selective COX-2/sEH dual inhibitors with potent analgesic/anti-inflammatory and cardioprotective properties |
2024 |
| 47 |
New pyrazole/pyrimidine-based scaffolds as inhibitors of heat shock protein 90 endowed with apoptotic anti-breast cancer |
2024 |
| 48 |
New series of 4, 6-diaryl pyrimidines: facile synthesis and antiproliferative activity as dual EGFR/VEGFR-2 inhibitors |
2024 |
| 49 |
Synthesis and characterization of new palladium (II) and silver (I) thiosemicarbazone derived by acenaphthenequinone complexes and their antimicrobial activity |
2024 |
| 50 |
Synthesis new series of 4-pyrazolylquinolinones with apoptotic antiproliferative effects as dual EGFR/BRAFV600E inhibitors |
2024 |
